—
C+
C+ The full Closelook — membership. Open the C+ overview

Johnson & Johnson (JNJ) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Johnson & Johnson

JNJ in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Johnson & Johnson develops, makes and sells healthcare products worldwide through two arms: Innovative Medicine, covering prescription treatments for cancer, immune disease, infection and heart and metabolic conditions, and MedTech, covering surgical, orthopaedic, cardiovascular and vision products, including contact lenses and lenses used in cataract surgery. It sells through wholesalers, distributors, hospitals and clinicians rather than direct to patients in most cases. It is based in New Brunswick, New Jersey.
Where it sits in the stack
The company carries no seat in our Rubin index, the diary's AI build-out gauge, so it sits outside that stack entirely. Within our wider universe it falls into the healthcare sector, drug manufacturers group, and the diary has grouped it among the slow-compounder names alongside consumer-staples and industrials peers in a covered-call income piece.
Who it is priced against
The diary has clustered it with other slow-moving dividend payers such as Coca-Cola, Procter & Gamble, Kimberly-Clark, 3M, Consolidated Edison, Abbott, Marsh McLennan, Emerson and Illinois Tool Works; the market's usual comparison beyond that list is Pfizer.
Why Closelook tracks it
It sits in the Dow Jones Industrial Average and turns up repeatedly in the diary's Daily Pulse notes, most often flagged by the Pattern Scanner as a support-confluence setup in a yellow regime. It carries no Closelook score, so that read is still being built. Analysts covering it have raised their price target, per the diary's most recent reading.
What the diary watches
Whether it keeps appearing among the Pattern Scanner's support-confluence names alongside cyclical stocks like Northrop Grumman and McDonald's, which the diary reads as a signal that defensive positioning is broadening.

Johnson & Johnson (JNJ) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: JNJ news on the tape · index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for JNJ, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by UBS, 2026-09-02

The Street on this name

Analyst actions and the latest print for JNJ from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target UBS — target 320 Target set to $320 (+18% to spot) 2026-09-02

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Johnson & Johnson (JNJ)?

Johnson & Johnson trades as JNJ on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is JNJ in a Closelook index?

Not currently — Johnson & Johnson is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does JNJ trade against its moving averages?

Uptrend stack intact: Trades +2.8% vs the 50-day and +13.6% vs the 200-day average, 3.9% below the 52-week high and +57.7% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Johnson & Johnson do?

Johnson & Johnson develops, makes and sells healthcare products worldwide through two arms: Innovative Medicine, covering prescription treatments for cancer, immune disease, infection and heart and metabolic conditions, and MedTech, covering surgical, orthopaedic, cardiovascular and vision products, including contact lenses and lenses used in cataract surgery. It sells through wholesalers, distributors, hospitals and clinicians rather than direct to patients in most cases. It is based in New Brunswick, New Jersey. The diary has clustered it with other slow-moving dividend payers such as Coca-Cola, Procter & Gamble, Kimberly-Clark, 3M, Consolidated Edison, Abbott, Marsh McLennan, Emerson and Illinois Tool Works; the market's usual comparison beyond that list is Pfizer.

Where does Johnson & Johnson sit in the AI build-out?

The company carries no seat in our Rubin index, the diary's AI build-out gauge, so it sits outside that stack entirely. Within our wider universe it falls into the healthcare sector, drug manufacturers group, and the diary has grouped it among the slow-compounder names alongside consumer-staples and industrials peers in a covered-call income piece. It sits in the Dow Jones Industrial Average and turns up repeatedly in the diary's Daily Pulse notes, most often flagged by the Pattern Scanner as a support-confluence setup in a yellow regime. It carries no Closelook score, so that read is still being built. Analysts covering it have raised their price target, per the diary's most recent reading.

What has Wall Street done on Johnson & Johnson recently?

The most recent analyst action on Johnson & Johnson on the Closelook wire is a price target by UBS on 2026-09-02 (target 320). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

Where has Closelook written about Johnson & Johnson?

Johnson & Johnson appears in 8 Closelook pieces, most recently Strategy: Covered Calls for Income — the Dividend Aristocrats Approach (2026-05-22); Daily Pulse: Temperature 59 — Rubin surges 25% monthly as cointegration breaks pile up (2026-05-14); Daily Pulse: Temperature 59 — first crack in semis, defensives bid (2026-05-13). What Closelook said most recently: The list overlaps heavily with the consumer-staples / industrials / healthcare slow-compounders: KO, PG, JNJ, KMB, MMM, ED, ABT, MMC, EMR, ITW, and on. (Strategy, 2026-05-22). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for JNJ, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 8 pieces · newest: Strategy, “Covered Calls for Income — the Dividend Aristocrats Approach” (2026-05-22)

Mentioned on Closelook

Where JNJ appears in the diary — 8 pieces, newest first. Every link is our own writing.

Long reads

Dailies

Related in the Closelook universe